Information for use of NIBSC monoclonal antibody panel for meningococcal typing

Specificity	mAb 'name' ¹	Source of mAb ²	NIBSC hybridoma number ³	Previous NIBSC order number	Current NIBSC order number	Approximate dilution of reconstituted stock for dot-blot ⁴	Approximate dilution of reconstituted stock for whole cell ELISA ⁴	Isotype	Reference
Group A	14-1-A	WRAIR 2D7B5B5B2	4039	95/674	95/674	1 in 300	1 in 100	IgG1	Wedege et al (1991). J. Clin. Microbiol. 29:1486-1492
Group B	2-2-B	WRAIR 5C1-3H7	4040	95/750	95/750	1 in 300	1 in 100	IgM	Mandrell & Zollinger (1982) J. Immunol. 129:2172-2178 Zollinger & Mandrell (1983) Infect. Immun. 40:257-264 Tsang & Zollinger (2005) Clin. Diagn. Lab. Immunol. 12:152-156
Group C	4-2-C	WRAIR 7H9-4	4041	95/678	95/678	1 in 300	1 in 100	IgG3	Tsang & Zollinger (2005) Clin. Diagn. Lab. Immunol. 12:152-156
Group W135	7-1-W	WRAIR 6G9-7	4044	Not previously available	In production	n/d	n/d	IgM	Tsang & Zollinger (2005) Clin. Diagn. Lab. Immunol. 12:152-156
Group Y	5-2-Y	WRAIR 2C2-4.2-G6	4043	Not previously available	To be produced in future?	n/d	n/d	IgM	Tsang & Zollinger (2005) Clin. Diagn. Lab. Immunol. 12:152-156
P3.1		NVI MN3C6B	4032	95/680	04/198	n/d	n/d	IgG2b	Poolman et al., (1995) Clin. Diagn. Lab. Immunol. 2:69-72
P2.2a	1-1-P2a	WRAIR 5D4-5	4055	95/682	02/180	1 in 250	1 in 1000	IgG3	Zollinger et al., (1984) Infect. Immun. 46:260-266
P2.2b	3-1-P2b	WRAIR 2H10-2	4056	95/684	Cells would not revive. Replaced with mAb from 4034 see below			IgG3	Zollinger et al., (1984) Infect. Immun. 46:260-266
P2.2b		NVI MN2C3B	4034	Not previously available	In production	n/d	n/d	IgG2a	Poolman et al., (1995) Clin. Diagn. Lab. Immunol. 2:69-72
P3.4		NVI MN14G21	4035	95/686	01/536	Neat or 1 in 10 (not useful for dot-blot)	1 in 500	IgG2a	Poolman et al., (1995) Clin. Diagn. Lab. Immunol. 2:69-72 Wedege et al (1991). J. Clin. Microbiol. 29:1486-1492 Urwin et al., Epidemiol. Infect. (1998) 121:95-101
P3.4	15-1-P4	WRAIR 5DC4C8G8	4058	Not previously available	02/308	1 in 500	1 in 500	IgG2b	Wedege et al (1991). J. Clin. Microbiol. 29:1486-1492 Urwin et al., Epidemiol. Infect. (1998) 121:95-101
P3.14		NVI MN5C8C	4036	95/688	In production	n/d	n/d	IgG2a	Poolman et al., (1995) Clin. Diagn. Lab. Immunol. 2:69-72
P3.15	2-1-P15	WRAIR 8B5-5-G9	4061	95/690	02/310	1 in 250	n/d	IgG2a	Poolman et al., (1995) Clin. Diagn. Lab. Immunol. 2:69-72 Zollinger et al., (1984) Infect. Immun. 46:260-266
P3.21	14-1-P21	WRAIR 6B11-F2-C11	4062	95/692	03/182	1 in 250	1 in 5000	IgG2a	Wedege et al (1991). J. Clin. Microbiol. 29:1486-1492
P1.1		NVI MN14C2.3	4020	95/694	03/114	1 in 500	1 in 5000	IgG2a	Poolman et al., (1995) Clin. Diagn. Lab. Immunol. 2:69-72
P1.2		NVI MN16C13F4	4021	95/696	02/178	1 in 1000	1 in 1000	IgG2a	Poolman et al., (1995) Clin. Diagn. Lab. Immunol. 2:69-72
P1.3	12-1-P1.3	WRAIR 5G8B2F9	4053	95/698	02/320	1 in 250	1 in 1000	IgG2a	Cruz et al. (1990) Epidemiol. Infect. 105:119-126
P1.4		NVI MN20B9.34	4022	95/700	02/148	1 in 250	1 in 10000	IgG2a	Poolman et al., (1995) Clin. Diagn. Lab. Immunol. 2:69-72
P1.5		NVI MN22A9.19	4023	95/702	03/226	1 in 250	1 in 5000	IgG2a	Poolman et al., (1995) Clin. Diagn. Lab. Immunol. 2:69-72
P1.6		NVI MN19D6.13	4024	95/704	03/210	1 in 250	1 in 1000	IgG3	Poolman et al., (1995) Clin. Diagn. Lab. Immunol. 2:69-72
P1.7		NVI MN14C11.6	4025	95/706	01/514	1 in 250	1 in 10000	IgG2a	Poolman et al., (1995) Clin. Diagn. Lab. Immunol. 2:69-72
P1.9		NVI MN5A10F	4026	95/708	In production	n/d	n/d	IgG2a	Poolman et al., (1995) Clin. Diagn. Lab. Immunol. 2:69-72
P1.10		NVI MN20F4.17	4027	95/710	03/224	1 in 250	1 in 10000	IgG2b	Poolman et al., (1995) Clin. Diagn. Lab. Immunol. 2:69-72
P1.12		NVI MN21A7.10	4028	95/712	04/122	1 in 125	n/d	IgG3	Poolman et al., (1995) Clin. Diagn. Lab. Immunol. 2:69-72
P1.13		NVI MN25H10.75	4063	95/714	03/236	1 in 125	1 in 5000	IgG2a	Wedege et al., (1995) Clin. Diagn. Lab. Immunol. 2:314-321
P1.14		NVI MN21G3.17	4029	95/716	03/142	1 in 500	n/d	IgG3	Poolman et al., (1995) Clin. Diagn. Lab. Immunol. 2:69-72
P1.15		NVI MN3C5C	4030	95/718	02/144	n/d	1 in 1000	IgG3	Wedege et al. (1999) Clin. Diagn. Lab. Immunol. 6:639-642
P1.16		NVI MN5C11G	4031	95/720	01/538	n/d	1 in 1000	IgG2b	Poolman et al., (1995) Clin. Diagn. Lab. Immunol. 2:69-72
P1.19	2-1-P1.19	WRAIR 7A2-11	4050	Not previously available	In production	n/d	n/d	IgG3	Wedege et al. (1999) Clin. Diagn. Lab. Immunol. 6:639-642
L3,7,9	9-2-L379	WRAIR 4BE12C10	4047	Not previously available	01/412	n/d	1 in 1000	IgG2a	Moran et al. (1994) Infect. Immun. 63:5290-5295

n/d = not done
WRAIR = Walter Reed Army Institute of Research
NVI = Netherlands Vaccine Institute (previously the RIVM)

Notes:

¹ mAb 'name': This was assigned at WRAIR and is the name used in the literature for the WRAIR mAbs .
² Source of mAb: This indicates the laboratory where the hybridoma cells were isolated and the hybridoma clone designation (this is also the name used in the literature for the NVI hybridomas).
³ NIBSC hybridoma stock number: this number was assigned at NIBSC when the hybridoma cells were received and refers to cells rather than antibody.
⁴ The dilutions given are for a stock solution of 1 ampoule reconstituted with 1ml water or phosphate buffered saline. The dilutions are given as a guide and reactivity with different meningococcal isolates will vary. The user should determine the best dilution to use in their own experimental system.